Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2009-04-22
2010-12-28
Sitton, Jehanne S (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
07858319
ABSTRACT:
Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNFα gene, the class 1 HLA genes, or a combination of both the TNFα and HLA genes.
REFERENCES:
patent: 2006/0046267 (2006-03-01), Mallal
patent: 434 450 (1991-06-01), None
Migueles et la; PNAS, Mar. 2000, vol. 97, pp. 2709-2714.
Henry, Review of Oral Abstract Session 24 of the 9thConference on Retroviruses and Opportunistic Infections, www.thebody.com/confs/rtro2002/henry2.html (retrieved from internet Oct. 5, 2005).
Hetherington et al., Genetic variation in HLA-B region and hypersensitivity reactions to abacavir, The Lancet 359:1121-1122 (Mar. 2002).
Hetherington et al., HLA-B57 and TNF-alpha Variants Associated with Hypersensitivity Reactions to Abacavir among HIV-1-Positive Subjects, 9thConference on Retroviruses and Opportunistic Infections, (Feb. 2002) (Abstract).
Mallal et al., Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, The Lancet 359:727-732 (Mar. 2002).
Mallal et al., The Presence of HLA-B*5701, -DRB1*0701, and -DQ3 is Highly Predictive of Hypersensitivty to the HIV Reverse Transcriptase Inhibitor Abacavir, 9thConference on Retroviruses and Opportunistic Infections, (Feb. 2002) (Abstract).
Pirmohamed et al., TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients, Neurology 56:890-896 (2001).
Pirmohamed et al., Genetic sysceptibility to adverse drug reactions, Trends in Pharmacological Sciences 22(6):298-305 (Jun. 2001).
Roses, Genome-Based Pharmacogenetics and the Pharmaceutical Industry, Nature Reviews 1:541-549 (Jul. 2002).
Migueles et al., PNAS, 97:2709-2714 (Mar. 2000).
Training Materials for Examining Patent Application with Respect to 35 U.S.C. 112, First Paragraph Enaglement of Chemical/Biotechnical Applications (pp. 1-65). Printed from USPTO website (www.uspto. gov) on Sep. 27, 2007).
Taylor, Genetic testing for inherited breast and ovarian cancer syndromes: important concepts for the primary ear physician, Postgrad Med J, 77:11-15 (2001).
Phillips et al., Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions—A Systematic Review, JAMA, 286(18):2270-2279 (Nov. 14, 2001).
Hughes et al., Pharmacogenetics, 14:335 (2004).
Rauch et al., Clin. Infect. Dis., 43:99 (2006).
Martin et al., Pharmacogenomics, 7:17 (2006).
Martin et al., PNAS, 101:4180 (2004).
Hughes et al., Pharmacogenmics, 5:203-211 (2004).
European Search Report for EP02756990 dated Jan. 4, 2005.
Vyakarnam et al., Abacavir induced hypersensitivity in HIV infected individuals is associated with an increased frequency of Th0 cells, AIDS (Hagerstown) 14(4):S65 (Oct. 2000).
Hetherington et al., Hypersensitivity reactions during therapy with abacavir analysis of 636 cases for clinical presentation and riskfactors, 7thConference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan. 30-Feb. 4, 2000.
Costello, et al, HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS, 13(14): 1990-1 (Oct. 1999).
Goulder, et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res. Human Retroviruses Dec. 10, 1996;12(18): 1691-8.
Klein, at al. Characterization of HLA-B57-restricted HIV type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J. Gen. Virol. 79(Pt 9): 2191-201 (Sep. 1998).
Migueles et al., Frequency and function of HIV-specific CD8(+) T cells, Immunol. Letters 79 (1-2): 141-50. 2001.
Hetherington Seth
Hughes Arlene R
Lai Eric H
Mosteller, Jr. Michael
Shortino Denise D
Campen Virginia G.
Sitton Jehanne S
SmithKline Beecham Corporation
LandOfFree
Method of screening for drug hypersensitivity reaction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of screening for drug hypersensitivity reaction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of screening for drug hypersensitivity reaction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4161739